The Quiet Consolidation Reshaping Orthopedic Surgery
Orthopedic surgery has long been the domain of independent, physician-owned ambulatory surgery centers – tight-knit operations built around a handful of surgeons, a loyal patient base, and the kind of procedural efficiency that hospitals frankly struggle to match. That model is now under serious pressure. Across the country, regional orthopedic ASCs are entering merger and acquisition conversations with larger ASC network operators, often with little public fanfare and even less regulatory scrutiny than comparable hospital deals.
The pace is accelerating. What started as opportunistic deal-making a few years ago has become a structured, well-financed consolidation wave, driven by private equity-backed ASC platforms looking to build scale in high-margin specialty surgery. Orthopedics – with its mix of joint replacements, spine procedures, and sports medicine cases – sits near the top of the target list.
Why ASC Networks Want Orthopedic Centers Now
The financial logic is straightforward. Orthopedic procedures generate strong, predictable revenue relative to their operating costs, particularly when performed outside the hospital setting. Total knee and hip replacements, once considered too complex for outpatient settings, have been approved for ASC-level care by Medicare in recent years. That regulatory change opened a door that private equity-backed platforms sprinted through.
ASC networks benefit enormously from owning orthopedic capacity rather than contracting for it. When a network controls the facility, it captures both the facility fee and the downstream scheduling, supply chain, and implant pricing leverage that comes with volume. A single high-performing orthopedic ASC can meaningfully move a network’s aggregate margin, which is why buyers are willing to pay multiples that would have seemed unrealistic five years ago.
Orthopedic surgeons, for their part, are frequently the ones initiating these conversations. Reimbursement pressure, rising malpractice costs, and the administrative burden of running an independent facility have made the economics of staying independent less attractive year over year. Selling a majority stake to a network – while retaining an equity position and clinical autonomy – looks appealing when the alternative is watching margins compress alone.
How the Deal Structures Actually Work
Most of these transactions are not outright sales. The dominant model involves a network operator acquiring a controlling interest – typically 51 to 60 percent – while the selling physicians retain a meaningful equity stake in the newly structured entity. The physicians continue to own a piece of the facility, participate in distributions, and in many cases hold management roles, but operational decisions around staffing, vendor contracts, and expansion fall increasingly to the acquiring platform.
This structure matters because it shapes how these deals are perceived by the surgeons involved. The pitch is partnership, not acquisition. The reality is that once a majority stake is transferred, the independence that defined these centers is largely gone, regardless of how the operating agreement is written.
The Competitive Pressure on Independent Holdouts
Regional orthopedic ASCs that have chosen to stay independent are now operating in a market where their consolidated competitors have structural advantages they cannot easily replicate. Larger networks negotiate implant pricing with major manufacturers at volumes that a three-surgeon center simply cannot match. That gap in supply costs alone can be several percentage points of margin – a difference that compounds over time.
Payer contracting is the other pressure point. ASC networks with geographic density can negotiate insurance reimbursement rates from a position of strength, because insurers cannot afford to exclude a network that controls a large share of outpatient surgical capacity in a region. An independent center negotiating the same contract is largely a price-taker. As networks build out regional clusters of orthopedic facilities, independent centers find themselves being reimbursed at rates that make reinvestment in equipment and staffing increasingly difficult.
This dynamic mirrors what has been happening in other specialty areas. Regional neurology practices have faced nearly identical pressure as private equity platforms built scale and used it to squeeze out independent operators through contracting advantages rather than clinical competition.
The practical question facing independent orthopedic ASC owners is less about whether to engage with a network and more about when and at what valuation. Timing matters considerably in these negotiations. Centers with strong case volume, diverse surgeon rosters, and clean payer mixes command premium multiples. Centers that wait until operational strain forces the conversation have less leverage. A growing number of orthopedic groups are working with M&A advisors to run structured processes – inviting multiple platform bidders rather than accepting the first overture – specifically to retain negotiating power before their independence becomes a liability rather than an asset.
What the long-term patient care implications of this consolidation look like remains genuinely unsettled. The efficiency argument for network-owned ASCs is real – standardized protocols, better implant contracts, and coordinated post-op care pathways can improve outcomes. But the incentive structure of a private equity-backed platform is built around EBITDA growth and eventual exit, not indefinite community service. When a network decides to rationalize capacity, close an underperforming center, or redirect case volume to maximize facility fees, the patients and surgeons at a formerly independent center have little recourse. That tension is baked into every deal being signed right now.
